CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Biopsy +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05105100
NCT05105100N/ACompleted
CompareCT.gov

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

University of California, San Francisco·observational·Posted Nov 3, 2021·Updated Apr 6, 2026

In Brief

An observational study evaluating Biopsy and Biospecimen Collection for Melanoma and Advanced Melanoma. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by tumor/blood small conditional RNA (scRNA) using T cell receptor (TCR) as a barcode and can help predict response to Programmed death-1 (PD-1) therapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Advanced Melanoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 3, 2021
Enrollment StartOct 29, 2021
Primary CompletionSep 15, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 4.7 years ago

Interventions

Biopsyprocedure

Tumor tissue collection

Biospecimen Collectionprocedure

Intravenously Blood draw